Paragonimus westermani antigen, recombinant protein and application of paragonimus westermani antigen

Through the highly specific and sensitive antigen PwS2B_4 and its recombinant protein, a kit and colloidal gold immunochromatography test strip were constructed, which solved the accuracy and speed of diagnosis of Wei's fumis fumis disease in traditional detection methods. The problem has achieved fast and accurate detection results.

CN118909069APending Publication Date: 2024-11-08INST OF PARASITIC DISEASE PREVENTION & CONTROL CHINESE CENT FOR DISEASE CONTROL & PREVENTION (NAT RES CENT FOR TROPICAL DISEASES)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411071859.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The detection rate of traditional Weician tidalis pathogenic detection standards is low and is often prone to misdiagnosis and misdiagnosis. The existing immunologic methods use soluble natural insect antigens, making it difficult to diagnose quickly and accurately.

Method used

It provides a highly specific and sensitive antigen PwS2B_4 and its recombinant protein. It can achieve rapid and accurate detection by constructing a kit and a colloidal gold immunochromatography test strip.

Benefits of technology

It has achieved rapid and accurate diagnosis of closed flukesomiasis, improved diagnostic effects, reduced misdiagnosis rate, and had good application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909069A_ABST
    Figure CN118909069A_ABST
Patent Text Reader

Abstract

The invention discloses a paragonimus westermani antigen, a recombinant protein and application of the paragonimus westermani antigen and the recombinant protein. The invention firstly discloses a paragonimus westermani antigen and a separated gene for coding the antigen, wherein the amino acid sequence of the antigen and the nucleotide sequence of the gene are respectively shown as SEQ ID NO.3 and SEQ ID NO.4. The invention further discloses a paragonimus westermani recombinant protein and application of the paragonimus westermani recombinant protein in preparation of a product for detecting, diagnosing or preventing paragonimus westermani disease. The amino acid sequence of the recombinant protein is shown as SEQ ID NO.6. The antigen and the recombinant protein are good in specificity, high in sensitivity and good in repeatability, the constructed kit and the constructed colloidal gold immunochromatography test strip can rapidly and accurately detect paragonimus westermani infection, and the problem that paragonimus westermani is difficult to rapidly and accurately diagnose in diagnosis in the prior art is solved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of biological gene engineering, and in particular to a Paragonimus westermani antigen, a recombinant protein and applications thereof. Background Art

[0004] The traditional etiological detection standard for Paragonimiasis westermani is to find eggs from sputum and feces, but the detection rate is low, and it is often easy to miss or misdiagnose. Therefore, etiological detection cannot meet the needs of clinical diagnosis. Immunological methods such as enzyme-linked immunosorbent assay (ELISA) are now widely used in auxiliary diagnostic detection of Paragonimiasis westermani, and soluble natural worm antigens (crude antigens) are generally used as detection antigens. However, if recombinant antigens can be used, the yield does not depend on worm extraction and pathogens, and can be produced on a large scale, which is more helpful to prevent the misdiagnosis of Paragonimiasis westermani. Finding recombinant antigens of Paragonimiasis westermani with better diagnostic effect is the key to improving the detection effect of ELISA. Therefore, establishing a rapid and accurate diagnostic method is an important means to prevent and control Paragonimiasis westermani. Summary of the invention

[0005] In view of the deficiencies of the prior art and actual needs, the present invention provides a Paragonimus westermani antigen, a recombinant protein and applications thereof. The antigen and recombinant protein of the present invention have good specificity, high sensitivity, good repeatability and can be mass-produced. The constructed kit and colloidal gold immunochromatographic test strip can quickly and accurately detect Paragonimus westermani infection, solving the problem that it is difficult to quickly and accurately diagnose Paragonimus westermani in the prior art.

[0006] The present invention provides a Paragonimus westermani antigen (PwS2B_4), the amino acid sequence of which is shown in SEQ ID NO.3.

[0007] The present invention also provides an isolated gene, which encodes the above-mentioned Paragonimus westermani antigen (PwS2B_4), and the nucleotide sequence of the gene is shown in SEQ ID NO.4.

[0008] The present invention also provides an antibody which specifically binds to the above-mentioned Paragonimus westermani antigen.

[0009] The present invention also provides a vector containing the isolated gene encoding the Paragonimus westermani antigen.

[0010] The present invention also provides a host cell, wherein the cell contains the above-mentioned vector, or the cell is transformed or transfected with the above-mentioned isolated gene.

[0011] The present invention also provides a detection reagent or a test kit, which contains the above-mentioned Paragonimus westermani antigen, the above-mentioned isolated gene encoding the above-mentioned Paragonimus westermani antigen, or an antibody that specifically binds to the above-mentioned Paragonimus westermani antigen (PwS2B_4).

[0012] The present invention also provides a recombinant protein, whose amino acid sequence is shown as SEQ ID NO.6.

[0013] The present invention also provides a recombinant protein expression vector, which contains the nucleotide sequence shown as SEQ ID NO.5.

[0014] The present invention also provides a recombinant host cell containing the above-mentioned recombinant protein expression vector.

[0015] The invention also provides a colloidal gold immunochromatographic test strip containing the above recombinant protein as an antigen.

[0016] The present invention also provides an antibody which specifically binds to the above recombinant protein.

[0017] The present invention also provides a detection reagent or a test kit, which contains the above-mentioned recombinant protein, or an antibody that specifically binds to the above-mentioned recombinant protein.

[0018] The present invention also provides the use of the above-mentioned Paragonimus westermani antigen (PwS2B_4), recombinant protein or any one of the above-mentioned detection reagents or kits in the preparation of products for detecting, diagnosing or preventing Paragonimus westermani disease.

[0019] The present invention also provides the use of an antibody that specifically binds to the above-mentioned Paragonimus westermani antigen (PwS2B_4) or an antibody that specifically binds to the above-mentioned recombinant protein in the preparation of a product for detecting, diagnosing or treating Paragonimus westermani disease.

[0020] The beneficial effects of the present invention are as follows: a PwS2B_4 antigen of Paragonimiasis westermani, a recombinant protein (recombinant antigen) and its application are provided, wherein the amino acid sequences of the antigen and the recombinant protein (recombinant antigen) are shown in SEQ ID NO.3 and SEQ ID NO.6, respectively. When the recombinant protein is used as a recombinant antigen, it has good antigenicity, good specificity, high sensitivity, and can be mass-produced. The kit and colloidal gold immunochromatographic test strip constructed by the same can quickly and accurately detect Paragonimiasis westermani infection, solving the problem that it is difficult to quickly and accurately diagnose Paragonimiasis westermani in the prior art diagnosis, and has good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 : Agilent 2100 detection chart of Paragonimus westermani total RNA, M: DNA marker; 1: total RNA.

[0022] Figure 2 : Signal peptide prediction results.

[0023] Figure 3 :Blastp sequence alignment analysis diagram of PwS_seq1.

[0024] Figure 4 : RT-PCR results of PwS2B_4 gene, M: DNA Marker, 1-3 are RT-PCR products.

[0025] Figure 5 : PCR results of constructing PwS2B_4 expression vector, M: DNA Marker, 1-2: PCR products.

[0026] Figure 6 : Purification of rPwS2B_4 recombinant protein, M: Protein marker, EA2-EA3: Elution buffer A (pH8.0), EB1-EB3: Elution buffer B (pH8.0), EC1-EC4: Elution buffer C (pH8.0), the soluble rPwS2B_4 recombinant protein is mainly concentrated in the eluate of Elution buffer C (EC1 tube).

[0027] Figure 7 : Scatter plot of specific antibodies in human serum detected by rPwS2B_4 recombinant protein ELISA. ●: Serum of patients with Paragonimiasis westermani; -: Serum of healthy people; ▲: Serum of patients with Clonorchiasis sinensis; ◆: Serum of patients with Schistosoma japonicum; ○: Serum of patients with Fasciola fascioliasis; ◇: Serum of patients with cysticercosis Threshold.

[0028] Figure 8 : PwS2B_4-colloidal gold immunochromatographic test strips test results of patient serum, Control: quality control strip, Test: test strip, 1-6: patient serum test results, 7-12: normal human serum test results. DETAILED DESCRIPTION

[0029] The specific implementation and technical scheme of the present invention are further described in detail below in conjunction with the accompanying drawings and specific examples, and the specific examples provide preferred implementations. In the present invention, unless otherwise specified, the raw materials can be purchased from conventional commercial products, and the equipment and testing methods are conventional equipment and methods in the art.

[0030] Example 1: Collection of Paragonimus westermani adults

[0031] Westermani metacercariae were isolated from crabs caught in Yongjia County, Wenzhou City, Zhejiang Province. 200 metacercariae were used to infect experimental dogs weighing about 10 kg. After 70 days, dog feces were collected to check for worm eggs. In accordance with the ethical requirements of experimental animal welfare, the infected dogs were killed and adult Paragonimus westermani were collected from the dog lungs.

[0032] Example 2: Isolation and purification of mRNA

[0033] Total RNA from adult Paragonimus westermani was extracted using Invitrogen's TRIzol reagent, and mRNA was isolated and purified from the total RNA according to the instructions of the Oligitex mRNA Spin-Column Kit. The quality of mRNA was tested by agarose gel electrophoresis and UV analysis ( Figure 1 ).

[0034] Example 3: Transcriptome sequencing and analysis of Paragonimus westermani adults

[0035] The sequencing and analysis of the transcriptome were completed by Shanghai Ouyi Biomedical Technology Co., Ltd. The SMART cDNA Library construction Kit from Clontech was used to construct the SMART cDNA library for sequencing. TM 2500 sequencer to complete large-scale transcriptome sequencing.

[0036] The original data of the obtained transcriptome was preprocessed to remove the adapter sequence and primer sequence, and to remove low-quality and short-length sequences. A total of 355,200 original unigenes were obtained after processing. The data of the original unigenes below 300 bp after splicing was 137,843. Transcripts above 300 (=355,200-137,843=217,357) were selected, and tgicl was used to remove redundancy, and the final unigene 57,406 were obtained.

[0037] Example 4: Searching for candidate antigen genes

[0038] By screening the transcriptome library of Pw adults, three Unigene sequences related to SAP protein were obtained, one of which was PwS_seq1.

[0039] The nucleotide sequence of PwS_seq1 is:

[0040] ATCCACGTAAGCACACGCAACAGTCAGCCAACGTGTCAAATTCCAAGGAACAACTGTCAACTAAATGGTATTTATAATGGGGATTCTATCCAGTTGGTGTTAAACGCTTCGAAATGAAGGCTGTTCTCTTCTTACTGGTCTCACTGGTTTCGCTCGTGGTTGCGGCCCCCCAAATCGACATACCGGATGATAACGATGCTGTGTGATGTTTGCAAGCAAACGGTGAAGACGATAAAGGATGGTATGAA AACAGGCATACTGCAACAAGTGCTTGAAATTTATTTGACAAAGCAGTGTGAGAGCCTTGGCATATTCGCTGAAGTTTGCAAATCGGCCATCAGCAAGGGCATCAAATTTTTGTCTGACCAAGTACAGAAGATGGAACCGGAAGAAACTTGTAGGAAAATCCGTTTATGCTGAACACTACCATGTCAAAAAAACCTGTTTGTAACGATGATGCGGAGAAACACGAAATAAACACTGATATTACCC(SEQ ID NO.1).

[0041] The amino acid sequence deduced by PwS_seq1 is:

[0042] MKAVLFLLVSLVSLVVAAPQIDIPDDNDACDVCKQTVKTIKDGMKTGILQQVLEIYLTKQCESLGIFAEV CKSAISKGIKFLSDQVQKMEPEETCRKIRLC (SEQ ID NO. 2).

[0043] SignalP5.0 software was used to analyze the amino acid sequence of PwS_seq1 online and predict the signal peptide. It was proved that the gene had a potential signal peptide cleavage site. At 17-18aa, the D value was 0.7571, indicating that 1-17aa in the amino acid sequence was a signal peptide sequence and the protein was a secreted protein containing a signal peptide ( Figure 2 ).

[0044]

[0045] Example 5: blastp sequence alignment analysis of PwS_seq1

[0046] The amino acid sequence of PwS_seq1 was analyzed by online blastp sequence alignment at NCBI. Figure 3 As shown in the figure, the amino acid sequence has a high homology with the amino acid sequences of two proteins through blastp sequence comparison analysis. Among them, the homology with the hypothetical protein P879_03910 [Paragonimus westermani] (GenBank: KAF8567804.1) is 97%; the homology with unknown, partial [Paragonimus westermani] (GenBank: AAK35218.1) is 81%. However, KAF8567804.1 is the annotation result of the genome of Paragonimus westermani by Korean scholar Choi, Y.-J; AAK35218.1 is a cDNA sequence screened by the author Ling Jiajian using the monoclonal antibody against Paragonimus adult worms. No further protein expression and functional studies have been conducted on the two.

[0047] Example 6: Cloning of PwS2B_4 gene

[0048] According to the nucleotide sequence of PwS_seq1, a reverse transcription primer (PwS_GSP: TCAGTGTTTATTTCGTG) (SEQ ID NO.7) was designed and the reverse transcription primer was used using SuperScript TM II RT reverse transcriptase was used to reverse transcribe the extracted total RNA of Paragonimus westermani. The obtained cDNA was used as a template and further PCR amplified by forward primer (PwS_4F: GCCCCCCAAATCGACATAC) (SEQ ID NO.8) and reverse primer (PwS_4R: GCATAAACGGATTTTCCTACAA) (SEQ ID NO.9). The reaction conditions were: 94℃5min; 94℃1 min; 57℃1min; 72℃3min, a total of 35 cycles; 72℃7min. RTPCT results are shown in Figure 4 The obtained PCR fragment was connected with the pGEM T-easy vector to construct the T_PwS_4 plasmid, which was transformed into E. coli DH5α, and the monoclonal colonies were selected for sequencing (sequencing by BGI), and the complete sequence of the mature peptide of the target protein was obtained. It was named PwS2B_4.

[0049] The deduced amino acid sequence of the PwS2B_4 gene is:

[0050] APQIDIPDDNDACDVCKQTVKTIKDGMKTGILQQVLEIYLTKQCDSLGIFAEVCKSAISKGIKFLSDQVQKMEPEETCRKIRLC (SEQ ID NO. 3).

[0051] The nucleotide sequence of the PwS2B_4 gene is:

[0052] GCCCCCCAAATCGACATACCGGATGATAACGATGCGGTGTGATGTTTGCAAGCAGACGGTGAAGACGATAAAGGATGGTATGAAAACAGGCATACTGCAACAAGTGCTTGAAATTTATTTGACAAAGCA GTGTGACAGCCTTGGCATATTCGCTGAAGTTTGCAAATCGGCCATCAGCAAGGGCATCAAATTTTTGTCTGACCAAGTACAGAAGATGGAACCGGAAGAAACTTGTAGGAAAATCCGTTTATGC(SEQ ID NO.4).

[0053] Example 7: Construction of PwS2B_4 recombinant protein expression vector

[0054] According to the PwS2B_4 gene sequence, the forward primer (PwS2BF: CATGCCATGGCCCCCCAAATCGACATA) (SEQ ID NO.10) and the reverse primer (PwS2BR3: CCGCTCGAGGCATAAACGGATTTTCCTACAA) (SEQ ID NO.11) were designed. Using the T_PwS_4 plasmid as a template, PCR amplification was performed (reaction conditions: 95℃5min; 94℃1 min; 57℃1min; 72℃3min, a total of 30 cycles; 72℃7min). PCR product ( Figure 5 ) was double-digested with NcoI_HF / XhoI, and ligated with pET28b plasmid double-digested with NcoI_HF / XhoI to successfully construct the pET28b-PwS2B_4 expression vector. It was further transformed into E.coliDH5a, amplified, and the plasmid was extracted. The sequence was verified to be correct by sequencing, and then transformed into E.coliBL21(DE3) competent cells.

[0055] The nucleotide sequence of pET28b-PwS2B_4 is:

[0056] TAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGCCCCCCAAATCGACATACCGGATGATAACGATGCGTGTGATGTTTGCAAGCAGACGGTGAAGACGATAAAGGATGGTATGAAAACAGGCATACTGCAACAAGTGCTTGAAATTTATTTGACAAAGCAGTGTGACAGCCTTGGCATATTCGCTGAAGTTTGCAAATCGGCCATCAGCAAGGGCATCAAATTTTTGTCTGACCAAGTACAGAAGATGGAACCGGAAGAAACTTGTAGGAAAATCCGTTTATGCCTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTG(SEQ ID NO.5).

[0057] The amino acid sequence of rPwS2B_4 is:

[0058] MAPQIDIPDDNDACDVCKQTVKTIKDGMKTGILQQVLEIYLTKQCDSLGIFAEVCKSAISKGIKFLSDQVQKMEPEETCRKIRLCLEHHHHHH(SEQ ID NO.6).

[0059] Example 8: Expression and purification of rPwS2B_4 recombinant protein

[0060] By optimizing and analyzing the induced expression conditions, the best induction conditions for the recombinant protein were determined to be: 1mmol / LIPTG at 37°C for 4 hours. After induction, the bacterial solution was centrifuged and the supernatant was discarded. An amount of BugBuster protein extractant (Novagen) approximately equal to the volume of the bacteria was added to the bacterial precipitate for lysis. The precipitate was fully suspended and centrifuged. The supernatant after centrifugation was fully combined with Ni-NTA Agarose and added to the treated column. After the Ni-NTA Agarose was precipitated, the yellow plug under the column was opened. After the liquid flowed out, the column was washed twice with Washing Buffer. The column was washed with Elution Buffer containing different concentrations of imidazole, and the eluate was collected in different Ep tubes. The collected liquid was subjected to SDS-PAGE electrophoresis for analysis to detect the effect of protein purification. Figure 6 As shown, the electrophoresis results showed that the recombinant protein rPwS2B_4 was mainly located in the supernatant and was a soluble protein.

[0061] Example 9: Evaluation of the effect of rPwS2B_4 recombinant protein on antibody detection

[0062] After the sera of patients with Paragonimiasis westermani were tested by indirect excretory secretory antigen (ESA)-ELISA, 10 sera with stronger reactions were mixed to form positive sera. Similarly, 10 sera of healthy people in non-epidemic areas were randomly mixed to form mixed negative control sera.

[0063] Coat the ELISA plate (Nunc, 96-well plate) with rPwS2B_4 recombinant protein at 4°C overnight, with a coating concentration of 0.5μg / ml, 100μl per well, and spin dry. Add 200μl of 1% BSA, block at 37°C for 1 hour, and wash three times with PBST. Add 100μl of 1:200 diluted patient serum, react at 37°C for 1 hour, and wash three times with PBST. Add 100μl of HRP-labeled goat anti-human IgG (Sigma, 1:10,000 dilution), react at 37°C for 1 hour, and wash four times with PBST. Add substrate TMB (Tiangen) for color development, and read the value at 450nm using an ELISA reader.

[0064] Identification of the antigenic reactivity of the rPwS2B_4 recombinant protein:

[0065] The above-mentioned indirect ELISA method was used to detect the antigenic reactivity of the rPwS2B_4 recombinant protein with mixed patient serum. The results are shown in Table 1. The OD value of the mixed positive serum is several times that of the mixed negative serum, indicating that the recombinant protein has good antigenic reactivity.

[0066] Table 1 ELISA test results of antigenic reactivity of rPwS2B_4 recombinant protein

[0067]

[0068] Evaluation of the diagnostic value of rPwS2B_4 recombinant protein:

[0069] The rPwS2B_4 recombinant protein was used to detect sera from 36 patients with Paragonimiasis westermani, 36 healthy controls, 15 patients with Clonorchiasis sinensis, 15 patients with Schistosoma japonicum, 15 patients with Fascioliasis and 15 patients with cysticercosis using the above-mentioned indirect ELISA method (coating concentration of 0.5 μg / ml) to evaluate the diagnostic value of the rPwS2B_4 recombinant protein.

[0070] like Figure 7 As shown in the figure, the average A450 values ​​of the serum groups of patients with Paragonimiasis westermani (Pw), healthy controls (Con), patients with Clonorchiasis sinensis (Cs), patients with Schistosoma japonicum (Sj), patients with Fascioliasis (Fg) and patients with cysticercosis (Cc) detected by rPwS2B_4 were 0.254±0.315, 0.054±0.023, 0.052±0.025, 0.036±0.013, 0.036±0.019 and 0.043±0.018, respectively. Taking 2.1 times the average value of the healthy controls as the positive threshold, the positive rate of patient seropositivity was 80.6% (29 / 36), and no positive results were detected in the sera of 36 healthy people, 15 patients with Fascioliasis, 15 patients with Schistosoma japonicum, 15 patients with cysticercosis and 15 patients with Clonorchiasis sinensis. The sensitivity, specificity and overall compliance of the ELISA method were 80.6%, 100.0% and 94.7%, respectively.

[0071] Example 10: Preparation of colloidal gold immunochromatographic test strips for detection of Paragonimus westermani-specific antibodies

[0072] A nitrocellulose membrane (NCM) is attached to the middle of a plastic base plate, and then a water-absorbing membrane and a reagent pad are attached to the longitudinal ends of the NCM, respectively. In the meantime, the water-absorbing membrane and the NCM and the NCM and the reagent pad are overlapped and connected at their junctions. Adhesive tape is applied to the junction of the NCM and the reagent pad as a flow control. Near the water-absorbing membrane of the NCM, Staphylococcus protein A (SPA) is coated horizontally in a linear shape as a quality control (Control, C) line. Near the reagent pad of the NCM, rPwS2B_4 soluble recombinant protein (concentration 0.2mg / ml) is coated horizontally in a linear shape as a detection (Test, T) line. 4mm wide strips are cut for standby use.

[0073] According to the method of Controlled Nucleation for the Regulation of the Particle Size in Monodisperse Gold Suspensions (Nat Phys, 1973, 241: 20-22) written by Frens G, chloroauric acid was reduced with trisodium citrate to prepare a colloidal gold solution with a particle diameter of 15 nm. According to the method of Colloidal Gold, Volume 1: Principles, Methods and Applications (Colloidal Gold: Principles, Methods and Application) (Academic press. San Diego, USA 1989: 1-39) written by Hayat MA, SPA-colloidal gold conjugate was prepared.

[0074] Place the colloidal gold immunochromatographic test strip on a flat surface, add 2 drops (80 μl) of SPA-colloidal gold reagent to the reagent pad of the test strip, and the former quickly enters the NCM. After the colloidal gold reagent enters the NCM, add 8 μl of the serum to be tested to the NCM at the end of the flow control tape. Observe (or scan and archive) the results within 5-10 minutes. Those with only C line are judged as negative; those with C and T lines are judged as positive; those without C line are judged as invalid. The results are as follows: Figure 8 shown.

[0075] Figure 8 In the figure, colloidal gold immunochromatographic strips 1-6 from left to right are the test results using the serum of patients with Paragonimiasis westermani. The results are displayed at the NCM at the end of the flow-control tape, with both C line and T line, indicating that the strip shows a positive result, verifying that the sera of the six patients are all infected with Paragonimiasis westermani. Colloidal gold immunochromatographic strips 7-12 are the test results using the serum of healthy people. The results are displayed at the NCM at the end of the flow-control tape, with only C line, indicating that the strip shows a negative result, verifying that the test results of the sera of the six normal people are all negative.

Claims

1. A Paragonimus westermani antigen, characterized in that Its amino acid sequence is shown in SEQ ID NO.

3.

2. An isolated gene, characterized in that The gene encodes the Paragonimus westermani antigen according to claim 1, and the nucleotide sequence of the gene is shown in SEQ ID NO.

4.

3. An antibody, characterized in that It specifically binds to the Paragonimus westermani antigen described in claim 1.

4. A carrier, characterized in that Contains the isolated gene according to claim 2.

5. A host cell, characterized in that The cell contains the vector of claim 4, or the cell is transformed or transfected with the isolated gene of claim 2.

6. A detection reagent or kit, characterized in that: Containing the antigen according to claim 1, the gene according to claim 2, or the antibody according to claim 3.

7. A recombinant protein, characterized in that Its amino acid sequence is shown in SEQ ID NO.

6.

8. A recombinant protein expression vector, characterized in that: The recombinant protein expression vector contains the nucleotide sequence shown as SEQ ID NO.

5.

9. A recombinant host cell, characterized in that Contains the recombinant protein expression vector according to claim 8.

10. A colloidal gold immunochromatographic test strip, characterized in that: Contains the recombinant protein according to claim 8 as an antigen.

11. An antibody, characterized in that It specifically binds to the recombinant protein described in claim 8.

12. A detection reagent or kit, characterized in that: Contains the recombinant protein according to claim 8, or the antibody according to claim 11.

13. Use of the antigen according to claim 1 or the recombinant protein according to claim 8 or the detection reagent or kit according to any one of claims 6 and 12 in the preparation of a product for detecting, diagnosing or preventing Paragonimiasis westermani.

14. Use of the antibody according to claim 3 or claim 11 in the preparation of a product for detecting, diagnosing or treating Paragonimiasis westermani.